CAJ | 학술논문

尽管化疗及造血干细胞移植被应用于急性髓系白血病(AML)的治疗,但仍然有大部分的患者在治疗后复发,少数患者在应用标准一线治疗方案后无法获得完全缓解.复发难治是目前导致AML患者治疗失败的主要原因,是当前AML治疗的重点和难点.对于复发难治性AML目前国际上尚无首选的化疗方案.文章就国内外成年人复发难治性AML(M3除外)的化疗现况及其进展进行综述.
진관화료급조혈간세포이식피응용우급성수계백혈병(AML)적치료,단잉연유대부분적환자재치료후복발,소수환자재응용표준일선치료방안후무법획득완전완해.복발난치시목전도치AML환자치료실패적주요원인,시당전AML치료적중점화난점.대우복발난치성AML목전국제상상무수선적화료방안.문장취국내외성년인복발난치성AML(M3제외)적화료현황급기진전진행종술.
Although intensive chemotherapy and hematopoietic stem cell transplant (HSCT) are currently used in the treatment of acute myeloid leukemia (AML),a large proportion of patients relapse after treatment.On the other hand,a minority of cases fail to achieve complete remission (CR) after a standard first line treatment.Leukemia relapse and refractory become the main course of treatment failure,which are also the main points and difficulties of treatment for AML.However,the most effective regimen for refractory/relapsed AML has not been established.This review focuses on the progress of the regimens and major chemotherapy for refractory/relapsed AML (except M3).